Manipal Health's Mega IPO: How India's Biggest Hospital Chain Makes Money

Most of us have walked into a Manipal hospital at some anxious moment — a parent's surgery, a late-night emergency, a health check we kept postponing. Few of us stopped to think that behind the reception desk sits one of India's largest businesses, and that it's about to invite the public to own a slice of it.

In July 2026, market regulator SEBI cleared Manipal Health Enterprises for an IPO that could value the company at around ₹1,00,000 crore (roughly $12 billion) — enough to make it India's most valuable listed hospital operator, leapfrogging Max Healthcare. Before anyone gets carried away, let's do what every investor should: understand how a hospital chain actually makes money, and where the risks hide. If IPOs are new to you, our what is an IPO explainer is a good first stop.

The scale, in plain numbers

Manipal runs 38 hospitals across India, employs over 11,058 doctors, and treated about 7.19 million patients in FY25. The IPO combines a fresh issue of ₹8,000 crore (new money into the company) with an offer for sale of about 4.32 crore shares by existing investors, led by Singapore's sovereign fund Temasek.

How does a hospital actually earn?

Strip away the white coats and a hospital is a business built on one expensive asset: beds. The core engine is how many beds are occupied (occupancy rate) and how much revenue each occupied bed generates per day — an industry metric snappily called ARPOB (average revenue per occupied bed). High-end specialities like cardiac care, oncology and transplants earn far more per bed than a general ward, so the mix of treatments matters enormously.

On top of that sit diagnostics, pharmacy, and out-patient consultations. The model is capital-heavy up front — land, buildings, MRI machines, ICUs cost a fortune — but once a hospital 'matures' and fills its beds, it can throw off healthy cash. That's the balancing act: pour crores into building, then wait years for occupancy to climb.

What the IPO money is for

Manipal plans to use the fresh proceeds mainly to cut debt — around ₹5,378 crore to repay borrowings — and about ₹574 crore to buy the remaining minority stake in Sahyadri Hospitals, a chain it has been absorbing. Paying down debt reduces interest costs and de-risks the balance sheet, which is exactly what a capital-heavy business wants before going public.

Strengths worth noting

• Scale and brand: being the largest by bed capacity brings negotiating power with suppliers and insurers, plus patient trust.
• A pan-India footprint spreads risk across cities and specialities rather than depending on one region.
• Marquee backers like Temasek signal institutional confidence and governance discipline.
• Structural tailwind: rising incomes, insurance penetration and an ageing population mean healthcare demand grows for decades.

And the risks — because there always are

• Capital intensity: building and equipping hospitals is expensive, and new units drag profits until they fill up.
• Regulation: the government caps prices on items like cardiac stents and knee implants, which can squeeze margins.
• Doctor dependence: star specialists drive footfall; losing them to a rival can dent a hospital's pull.
• Competition: Apollo, Max, Fortis and regional chains are all expanding and acquiring aggressively.
• Valuation: a ~₹1 lakh crore tag prices in a lot of future growth — a listing being large and famous doesn't automatically make it cheap.

A hospital's balance sheet is patient: it heals slowly, one occupied bed at a time. Investors in it need the same patience.

The lesson for investors

Manipal's IPO is a clean case study in reading past the headline. 'India's biggest hospital chain' is a great story, but the questions that matter are boringly specific: how full are the beds, how fast is ARPOB rising, how heavy is the debt after the IPO, and is the price fair for the growth on offer? To even apply, you'll need a demat account; to judge the business, compare it with other listings like our SBI Funds Management IPO case study and notice how each makes money differently.

Whether or not Manipal ends up in anyone's portfolio, it's a masterclass in how a familiar service — a hospital bed — becomes a business you can analyse. The story is big; the homework is small and specific. Do the small homework.

Over to you: would you invest in a business you've literally been a customer of, or does knowing a brand make you less objective about its numbers? Tell us how you'd approach it. This is educational content, not investment advice.